Menopause Is Not a Gumboil: Answering Clinical Misunderstandings in Light of Medscape
Menopause is one of the major physiological stages in a woman’s life, as natural as childhood, adulthood and old age. It marks the end of reproductive function, but not the end of health, agency or dignity. Yet in contemporary medicine, menopause is often treated as a problem to be fixed rather than a normal biological transition to be understood.
Recently, a Medscape article on the “hidden burdens” of menopause presented a detailed catalogue of new symptom clusters and proposed multiple interventions. It is a useful clinical document, but it raises a deeper question: are we still thinking about menopause itself as a physiological period in a woman’s life, or have we begun to treat the life stage as a disease?
In this essay, we argue that menopause and postmenopause are physiological stages. Good clinical practice must start from this fact. Only on this basis can we distinguish genuine disease from the ordinary signs of a life stage, avoid misdiagnosis, and use hormone therapy and other treatments as tools for maladaptation rather than as attempts to correct a natural state.
Menopause as a natural stage in women’s biology
Standard medical definitions describe natural menopause as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity, usually around the age of 50, when a woman has had 12 consecutive months with no menstrual bleeding. This process is not, in itself, classified as a disease; it is a normal part of aging and marks the end of reproductive capacity.
Postmenopause is the period that follows. Biologically, it is a genetically programmed and natural stage that often comprises at least one‑third of a woman’s life. Global statistics confirm that women, on average, live longer than men in most countries, and as life expectancy rises, women increasingly outlive men. Nature does not abandon women once reproduction ends; in many populations women’s maximum lifespan exceeds that of men by several years.
During reproductive years, women have lower rates of many cardiovascular diseases than men. After the reproductive period, their survival advantage often persists. The organism has been equipped with biological clocks that regulate the onset and offset of reproduction. One of the “windows” in these clocks is estrogen, with levels that differ across pre‑reproductive, reproductive and post‑reproductive stages. A decrease in estrogen production in postmenopause is therefore not automatically “deficiency”; it is the normal level for this stage of life.
This point is crucial for clinical language. If hormone levels that are appropriate for postmenopause are described simply as “deficient,” clinical reasoning begins from loss and pathology rather than from age‑appropriate physiology. A biology‑first view starts differently: hormone patterns in postmenopause reflect the fact that the organism has entered another natural stage with its own internal logic, risks and adaptive demands.
How the Medscape article broadens the clinical picture
The Medscape article on the “hidden burdens” of menopause performs an important service. It reminds clinicians that menopause is not only about hot flashes and night sweats. It highlights musculoskeletal syndrome of menopause (MSM), genitourinary syndrome of menopause (GSM), oral symptoms, auditory symptoms such as tinnitus, nasal and olfactory changes, and obstructive sleep apnea as problems that may emerge or become more evident around and after the menopausal transition.
GSM is described as a common condition resulting from declining estrogen and androgen concentrations, with symptoms such as vulvovaginal dryness, burning, itching, dyspareunia, dysuria, urinary urgency and recurrent urinary tract infections. Unlike vasomotor symptoms, GSM rarely improves spontaneously and tends to worsen over time without treatment. MSM is defined as a constellation of musculoskeletal pain, arthralgia, loss of lean muscle mass, reduced bone density, increased tendon and ligament injury and adhesive capsulitis, all influenced by changes in estrogen.
The article also calls attention to less familiar domains:
Oral dryness, burning mouth, changes in microbiome, tooth microfractures and bruxism.
Hearing loss, auditory sensitivity, tinnitus and itchy ears.
Rhinitis, rhinosinusitis and olfactory dysfunction.
An increased risk of obstructive sleep apnea in postmenopausal women, even in the absence of obesity or loud snoring.
In each case, clinicians are advised to consider the role of estrogen decline, evaluate for these conditions, and discuss treatment options, including hormone therapy in appropriate candidates, along with lifestyle, physical therapy, dental care and sleep studies.
This broader clinical map is helpful in preventing neglect. It warns practitioners against reducing menopause to one or two symptoms and encourages them to ask whether musculoskeletal pain, genitourinary complaints, sleep problems or sensory changes might be parts of larger, menopause‑associated syndromes that deserve attention.
Where symptom‑centered thinking can drift away from biology
Difficulties begin when a useful symptom inventory becomes the primary framework for understanding menopause. If every complaint that becomes more common after age 50 is quickly drawn into a menopause‑centered explanatory model, clinicians can overattribute symptoms to menopause and underrecognize vascular, metabolic, neurologic, psychiatric, dental or lifestyle‑related causes that require separate evaluation.
The Medscape article itself cautions that new symptoms remote from menopause onset should not automatically be explained by low estrogen and that other causes must be ruled out. Nevertheless, the overall emphasis reflects a style of practice in which clinicians are encouraged to actively search for additional menopause‑linked syndromes and then consider intervention. This is often reasonable, but it can also narrow diagnostic thinking. There is a subtle shift from treating diseases that may occur during postmenopause to treating menopause itself as the underlying clinical problem.
A biology‑first approach inverts this order. It begins from the recognition that menopause is a physiological transition and asks, for each woman, whether her adaptation to this stage is successful or impaired. Only when adaptation fails—when musculoskeletal changes cohere into MSM that impairs function, when urogenital changes become GSM with recurrent infections, when sleep changes become clinically significant obstructive sleep apnea—does the picture cross from physiology into pathology.
Physiology first, pathology second
From this perspective, we can distinguish three levels:
Physiological menopause and postmenopause – natural life stages with appropriate hormonal patterns and expected biological changes.
Maladaptation in menopause – symptom complexes such as MSM, GSM or obstructive sleep apnea that reflect difficulties in adaptation to the physiological transition and may require support.
Independent disease processes – broader vascular, metabolic, autoimmune, neurologic or psychiatric illnesses that may emerge or accelerate during postmenopause but are not reducible to menopause itself.
Good clinical practice situates women within this structure. It does not deny that menopause can be a challenging time, nor that MSM, GSM or sleep apnea may have real impacts on health and quality of life. Instead, it locates these problems within a hierarchy: menopause is physiological; maladaptation and disease require diagnosis and treatment; and the goal of care is to support adaptation, reduce risk and alleviate suffering without medicalizing a life stage as such.
Why misdiagnosis and overtreatment become possible
When menopause is treated too broadly as a clinical explanation, diagnostic errors can occur in two directions.
On one side, serious diseases may hide behind the convenient label of “menopause.” A woman with atherosclerotic cardiovascular disease, arterial hypertension, diabetes, sleep disorders or major depression may be reassured that her problems are “just menopause,” delaying appropriate investigation and treatment.
On the other side, ordinary biological changes may be overmedicalized, leading women to be treated as though they are ill simply because they have entered postmenopause. If every joint ache, every change in the mouth or nose, every variation in sleep is assumed to be “menopausal,” the threshold for prescribing grows lower and women are subtly encouraged to see their life stage as pathology.
Cardiovascular thinking shows the risk clearly. Menopause is associated with changes in vascular risk factors, but atherosclerosis and hypertension are age‑related, multifactorial conditions shaped by genetics, metabolism, environment and lifestyle. Reducing such disorders to estrogen loss alone oversimplifies causation and misdirects therapy—encouraging hormonal solutions where lipid management, blood pressure control and lifestyle interventions are primary.
Similarly, musculoskeletal pain or genitourinary complaints may be quickly labeled “menopausal” when they are driven by mechanical injury, infection, pelvic floor dysfunction, systemic inflammatory disease or other distinct mechanisms. In each case, an exclusive menopause‑centered lens can obscure the need for broader differential diagnosis.
The place of menopausal hormone therapy
Menopausal hormone therapy (HT) has an important and legitimate place in care when its role is properly understood. Contemporary guidance generally supports systemic HT for appropriate symptomatic women—typically those younger than 60 years or within 10 years of menopause—when benefits outweigh risks and contraindications are absent. HT can reduce vasomotor symptoms, preserve bone density, and improve some aspects of genitourinary and sleep‑related health.
However, HT should not be treated as a general correction for postmenopausal biology. It is better understood as a targeted tool for maladaptation: a way to lessen severe vasomotor symptoms, alleviate GSM, support sleep or quality of life in selected patients, and in some contexts help with aspects of MSM or other symptom complexes under careful clinical judgment. The aim is not to reverse menopause or restore reproductive hormone levels indefinitely, but to reduce pathological consequences when adaptation has become impaired.
This view also supports respect for individual variation. Some women pass through menopause with minimal symptoms and no need for HT. Others have significant GSM or MSM and benefit greatly from local vaginal estrogen, DHEA, ospemifene, systemic HT or non‑hormonal therapies. Recognizing menopause as physiological does not mean ignoring suffering; it means ensuring that treatment responds to true pathology and maladaptation rather than to the mere fact of being in a natural stage.
A clinical language closer to women’s biology
Clinical language should reflect women’s biology more faithfully. Instead of speaking as though menopause itself is pathological, clinicians can describe it as a natural stage and reserve disease language for clinically important deviations, complications or maladaptive syndromes.
This shift is not merely semantic. It changes how women are listened to, how diagnoses are made and how treatment is justified. A woman in postmenopause does not need to be rescued from her biology; she needs her biology to be understood well enough that true disease is neither missed nor invented.
Symptom inventories and treatment algorithms—like those highlighted in the Medscape article—have value, but they should remain secondary to a biology‑first understanding in which postmenopause is recognized as a normal human stage and medical intervention is reserved for genuine pathology, impaired adaptation or meaningful suffering.
Conclusion: physiology as the anchor
The strongest menopause medicine begins with respect for the natural architecture of women’s life. Menopause and postmenopause are physiological stages, shaped by evolutionary and biological design, associated with both challenges and advantages. Clinical practice that starts from this recognition can integrate MSM, GSM, sleep apnea, cardiovascular disease and other conditions into a coherent picture without collapsing them into a single label.
Articles such as the Medscape piece help map symptom burdens, but they should be read through a biological lens that distinguishes normal transition from maladaptation and disease. When physiology is the anchor, diagnosis becomes more precise, treatment more appropriate and the lived reality of postmenopause more dignified.
You can learn more by reading this our article
Comments
Post a Comment